NCT06752876View on ClinicalTrials.gov

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2027

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Systemic Lupus ErythematosusLupusLupus ErythematosusLupus Nephritis
Interventions
DRUG

CB-010

CB-010 allogeneic CAR-T cell therapy, Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

Sponsors
All Listed Sponsors
lead

Caribou Biosciences, Inc.

INDUSTRY